R&D(research and development)

Products/Pipeline

Drug Development Pipeline(As of SEP.2016)

※Note: F351 is a New Chemical Entity derivation of F647/Etuary®.

Products

Approved Drug

Etuary®(艾思瑞® in Chinese)
Indication : Idiopathic Pulmonary Fibrosis (Obtained Manufacturing and Distribution Permission in December, 2013) (Start selling as the Class 1.1 in February, 2014)

Clinical Development Stage

Etuary®(艾思瑞® in Chinese)
Radiation-induced Pneumonitis:Launched pre-Phase III clinical trial pilot study
F351
Indication: Liver Fibrosis- Phase II clinical trials, June.2015
Indication: Chronic Kidney Failure (CKD)- Preclinical stage
Tamibarotene
Indication: Acute promyelocytic leukemia(APL)- Preparation for Import Permit application

IND(Investigational new drug application) Stage

Etuary®(艾思瑞® in Chinese)
Indication: Diabetic Nephropathy(DN)-January.2014
Indication: Connective Tissue Disease Associated Interstitial Lung Disease (CTD-ILD) -October.2014
F573
Indication: Acute liver failure/ Acute-on-chronic liver failure (ACLF) -July.2011